713 results on '"Bosse, Tjalling"'
Search Results
2. Deep learning detects premalignant lesions in the Fallopian tube
3. Molecular Classification Outperforms Histologic Classification in Prognostication of High-grade Endometrial Carcinomas With Undifferentiated and Sarcomatous Components
4. Automated causal inference in application to randomized controlled clinical trials
5. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials
6. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
7. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome
8. Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE
9. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
10. Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines
11. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
12. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
13. HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva
14. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance
15. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories
16. Prediction of recurrence risk in endometrial cancer with multimodal deep learning
17. Patterns of cytotoxic T-cell densities in immunogenic endometrial cancers reveal a potential mechanism for differences in immunotherapy efficacy
18. Automated causal inference in application to randomized controlled clinical trials
19. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
20. Does "One Size Fits All"? Rethinking FIGO Depth of Invasion Measurements in Vulvar Cancer.
21. Prognostic value of molecular classification in stage IV endometrial cancer
22. Abstract IA014: Personalized adjuvant treatment in endometrial cancer
23. Data Set for the Reporting of Carcinomas of the Vagina: Recommendations From the International Collaboration on Cancer Reporting (ICCR)
24. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes
25. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
26. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
27. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status
28. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome
29. HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer.
30. FIGO 2023 endometrial cancer staging: too much, too soon?
31. SO019LBA/#875 Molecular features predicts outcomes in multicentric international study of chemoradiation and MRI based image guided brachytherapy for cervical cancer (EMBRACE): final analysis from bioembrace-I
32. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials
33. PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
34. Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer
35. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
36. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies
37. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
38. The immune cell infiltrate in the microenvironment of vulvar Paget disease
39. Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival
40. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas
41. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis
42. 3408: Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer
43. Gynaecological neoplasms in common familial syndromes (Lynch and HBOC)
44. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
45. QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
46. MLH1Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome
47. Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
48. FIGO 2023 endometrial cancer staging: too much, too soon?
49. RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test.
50. Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.